Phase I, Dose-ranging, Open-label, Study of a Single Administration of T-cells Add-back Depleted of Host Alloreactive Cells Using Theralux™ Therapy, Following Haploidentical Peripheral Blood Stem Cell Transplantation Submitted to CD34+ Cell Selection, in Patients With Severe Hematologic Malignancies

Trial Profile

Phase I, Dose-ranging, Open-label, Study of a Single Administration of T-cells Add-back Depleted of Host Alloreactive Cells Using Theralux™ Therapy, Following Haploidentical Peripheral Blood Stem Cell Transplantation Submitted to CD34+ Cell Selection, in Patients With Severe Hematologic Malignancies

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs T cell replacement therapy TH 9402 (Primary)
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia; Leukaemia; Lymphoma; Multiple myeloma; Myelodysplastic syndromes
  • Focus Adverse reactions; Proof of concept
  • Sponsors Kiadis Pharma
  • Most Recent Events

    • 19 Sep 2017 According to a Kiadis Pharma media release, results from this trial were presented at the 4th Cell and Gene Therapy Conference.
    • 03 Sep 2014 Results published in a Kiadis Pharma Media Release.
    • 29 Apr 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top